News_en

Taipei, Taiwan | January 19, 2026 YC Biotech announced today that its strategic partner, JY-Biomed, has received official notification from the U.S. Food and Drug Administration (FDA) regarding the Investigational New Drug (IND) application for Stemis™ (IND 32415). The FDA has cleared the IND, allowing the clinical trial to proceed. Following this significant regulatory greenlight, YC Biotech will assist JY-Biomed in leveraging this US clearance […]

Taipei, Taiwan | January 09, 2006 YC Biotech announced today that it has successfully assisted its partner, SL Bio, in reaching regulatory alignment with the U.S. FDA regarding the development pathway for CTA-001, following a productive INTERACT meeting (Meeting ID: 22044). This engagement provided key expert guidance from the Agency, significantly accelerating the program’s transition toward clinical development.  CTA-001 consists of autologous T cells expanded

Taipei, Taiwan | December 15, 2025 YC Biotech announced today that it has successfully assisted its strategic partner, JY-Biomed, in completing a formal regulatory engagement with the U.S. FDA regarding the IND development strategy for ExoVeris™ (Meeting ID: 22002). Through this Pre-IND meeting, the companies have obtained clear regulatory guidance on clinical, CMC (Chemistry, Manufacturing, and Controls), and non-clinical study designs, setting a definitive

In April 2025, JY Biomed Inc. and YC Biotech Inc. jointly announced the submission of their collaborative regenerative medicine clinical study for Parkinson’s Disease (PD) to the Joint Institutional Review Board of Taipei Medical University and its affiliated hospitals.  This study centers on the use of mesenchymal stem cells (MSCs) to evaluate their potential therapeutic

Taipei City | Date: February 4, 2025 regeneratiYC Biotech Co., Ltd. announced recently that it will conduct an innovative animal study on hair follicle regeneration, scheduled to begin in February 2025. This nearly year-long research will evaluate the efficacy of hair follicle stem cell exosomes in promoting hair growth. This prospective study will conduct a

Taipei City | Date: January 16, 2025 As Taiwan’s population continues to age, osteoarthritis has become an increasing burden on patients’ mobility and quality of life, leading to a growing demand for effective treatments. To improve patient well-being, YC Biotech Co., Ltd. is launching an innovative clinical study focused on knee osteoarthritis treatment. The study

Based on their long-standing academic exchange foundation, YC Biotech and Odawara Hakone Kenshin Clinic have jointly created a precision medicine ecosystem that integrates the strengths of both Taiwan and Japan. In addition to providing services through Odawara Hakone Kenshin Clinic’s state-of-the-art equipment, YC Biotech has exclusively introduced leading Taiwanese biotech brand Ji Yan Biomedical’s stem

Taipei City | Date: January 14, 2025 YC Biotech Co., Ltd. is actively expanding its clinical research footprint in the field of aesthetic medicine. The company recently announced the launch of an innovative clinical research project at Shuang Ho Hospital, part of the Taipei Medical University Healthcare System. This study will focus on evaluating the

Taipei City – January 7, 2025 Dr. Lee, renowned for her expertise in treating hair loss, was specially invited to lead this trial due to her exceptional professional background and achievements. A graduate of Taipei Medical University with advanced training at Harvard University, Dr. Lee previously served as Director of the Medical Aesthetics and Cosmetics